Tocilizumab, a humanized anti-IL.6 receptor antibody, has been approved as a biological drug for the treatment of rheumatoid arthritis, Castleman's disease and systemic JIA, and is expected to be ...

New research from Tokyo, Japan could help clarify the role of proinflammatory mediators in the pathogenesis of chronic inflammatory myopathies, such as polymyositis and dermatomyositis. Elevated ...